Bold opening statement: A groundbreaking cellular therapy now offers new hope for severe aplastic anemia, potentially changing the long arc of this life-threatening condition. But here's where it gets controversial: not everyone agrees on the best way to interpret and apply this new option, especially given limited long-term data and the complexities of donor availability. And this is the part most people miss: real-world access, pricing, and equitable use will shape how transformative this therapy actually becomes.
Rewritten content:
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
FDA News Release
For Immediate Release:
December 08, 2025
The U.S. Food and Drug Administration today announced the approval of Omisirge (omidubicel-onlv), marking the first hematopoietic stem cell transplant (HSCT) therapy specifically indicated to treat adults and pediatric patients aged 12 years and older with hematologic malignancies, and now approved for adults and pediatric patients aged six years and older with severe aplastic anemia (SAA) after reduced-intensity conditioning and in cases where a fully matched donor is not available.
“This approval reshapes the therapeutic landscape and has the potential to alter the life trajectory for patients with SAA, where earlier intervention can be pivotal,” said Vinay Prasad, M.D., M.P.H., Chief Medical and Scientific Officer and Director of the FDA’s Center for Biologics Evaluation and Research. “Severe aplastic anemia is a rare, potentially fatal blood disorder, and the FDA remains committed to expanding treatment options for those affected.”
SAA is a rare, life-threatening condition in which the bone marrow fails to produce sufficient red blood cells, white blood cells, and platelets. Treatment choices depend on age and typically include immunosuppressive therapy and/or HSCT, ideally from a matched sibling or related donor. When a donor isn’t available, clinicians may consider umbilical cord blood transplantation. However, cord blood transplants can involve slower hematopoietic recovery and higher infection risks. Omisirge uses donated cord blood stem cells that have been chemically enhanced with nicotinamide (a form of vitamin B3) and then infused into the patient to help reconstitute the blood and immune systems.
Omisirge addresses the limitations associated with umbilical cord blood sources, such as delayed recovery and increased infections, and expands graft options for people with SAA who require HSCT.
“Omisirge represents a novel stem cell product derived from umbilical cord blood and will provide a therapeutic option for patients with severe aplastic anemia who have limited transplant choices,” stated Megha Kaushal, M.D., M.S., Acting Deputy Director of the CBER Office of Therapeutic Products and pediatric hematologist. “By shortening the time to neutrophil recovery, Omisirge may speed post-transplant recovery and potentially reduce infection risk in this patient group.”
The safety and effectiveness of Omisirge were evaluated in an ongoing, open-label, prospective, single-arm study involving patients aged six years and older with SAA. In the efficacy population, Omisirge produced early and sustained neutrophil engraftment in 12 of 14 patients, with a median neutrophil recovery time of 11 days (ranging from seven to 20 days).
Common adverse effects observed with Omisirge include febrile neutropenia, viral and bacterial infections, hyperglycemia, immune thrombocytopenia, and pneumonia. Autoimmune cytopenias occurred in about 25% of patients.
The application benefited from Orphan Drug and Priority Review designations. The FDA granted approval of Omisirge to Gamida Cell Ltd.
Consumer contact: 888-INFO-FDA
Boilerplate
The FDA, an agency within the U.S. Department of Health and Human Services, protects public health by ensuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use, as well as medical devices. The agency also oversees the safety of the nation’s food supply, cosmetics, dietary supplements, radiation-emitting devices, and tobacco products.
